Prospective Detection of Early Lung Cancer in Patients With COPD in Regular Care by Electronic Nose Analysis of Exhaled Breath

Abstract

BackgroundPatients with COPD are at high risk of lung cancer developing, but no validated predictive biomarkers have been reported to identify these patients. Molecular profiling of exhaled breath by electronic nose (eNose) technology may qualify for early detection of lung cancer in patients with COPD.Research QuestionCan eNose technology be used for prospective detection of early lung cancer in patients with COPD?Study Design and MethodsBreathCloud is a real-world multicenter, prospective, follow-up study using diagnostic and monitoring visits in day-to-day clinical care of patients with a standardized diagnosis of asthma, COPD, or lung cancer. Breath profiles were collected at inclusion in duplicate by a metal-oxide semiconductor eNose positioned at the rear end of a pneumotachograph (SpiroNose). All patients with COPD were managed according to standard clinical care, and the incidence of clinically diagnosed lung cancer was prospectively monitored for 2 years. Data analysis involved advanced signal processing, ambient air correction, and statistics based on principal component (PC) analysis, linear discriminant analysis, and receiver operating characteristic analysis.ResultsExhaled breath data from 682 patients with COPD and 211 patients with lung cancer were available. Thirty-seven patients with COPD (5.4%) demonstrated clinically manifest lung cancer within 2 years after inclusion. PCs 1, 2, and 3 were significantly different between patients with COPD and those with lung cancer in both training and validation sets with areas under the receiver operating characteristic curve (AUCs) of 0.89 (CI, 0.83-0.95) and 0.86 (CI, 0.81-0.89). The same three PCs showed significant differences (P < .01) at baseline between patients with COPD who did and did not subsequently demonstrate lung cancer within 2 years, with a cross-validation value of 87% and AUC of 0.90 (CI, 0.84-0.95).InterpretationExhaled breath analysis by eNose identified patients with COPD in whom lung cancer became clinically manifest within 2 years after inclusion. These results show that eNose assessment may detect early stages of lung cancer in patients with COPD. Patients with COPD are at high risk of lung cancer developing, but no validated predictive biomarkers have been reported to identify these patients. Molecular profiling of exhaled breath by electronic nose (eNose) technology may qualify for early detection of lung cancer in patients with COPD. Can eNose technology be used for prospective detection of early lung cancer in patients with COPD? BreathCloud is a real-world multicenter, prospective, follow-up study using diagnostic and monitoring visits in day-to-day clinical care of patients with a standardized diagnosis of asthma, COPD, or lung cancer. Breath profiles were collected at inclusion in duplicate by a metal-oxide semiconductor eNose positioned at the rear end of a pneumotachograph (SpiroNose). All patients with COPD were managed according to standard clinical care, and the incidence of clinically diagnosed lung cancer was prospectively monitored for 2 years. Data analysis involved advanced signal processing, ambient air correction, and statistics based on principal component (PC) analysis, linear discriminant analysis, and receiver operating characteristic analysis. Exhaled breath data from 682 patients with COPD and 211 patients with lung cancer were available. Thirty-seven patients with COPD (5.4%) demonstrated clinically manifest lung cancer within 2 years after inclusion. PCs 1, 2, and 3 were significantly different between patients with COPD and those with lung cancer in both training and validation sets with areas under the receiver operating characteristic curve (AUCs) of 0.89 (CI, 0.83-0.95) and 0.86 (CI, 0.81-0.89). The same three PCs showed significant differences (P < .01) at baseline between patients with COPD who did and did not subsequently demonstrate lung cancer within 2 years, with a cross-validation value of 87% and AUC of 0.90 (CI, 0.84-0.95). Exhaled breath analysis by eNose identified patients with COPD in whom lung cancer became clinically manifest within 2 years after inclusion. These results show that eNose assessment may detect early stages of lung cancer in patients with COPD. Take-home PointsStudy Question: Can electronic nose (eNose) technology be used for prospective detection of early lung cancer in patients with COPD?Results: The eNose was able to discriminate patients with COPD who subsequently received a lung cancer diagnosis from those who did not receive such a diagnosis with 87% accuracy, an area under the receiver operating characteristic curve of 0.90 (95% CI, 0.84-0.95), 86% sensitivity, and 89% specificity.Interpretation: These results show that eNose assessment may detect early stages of lung cancer in patients with COPD and therefore may be of value in screening this risk group. Study Question: Can electronic nose (eNose) technology be used for prospective detection of early lung cancer in patients with COPD? Results: The eNose was able to discriminate patients with COPD who subsequently received a lung cancer diagnosis from those who did not receive such a diagnosis with 87% accuracy, an area under the receiver operating characteristic curve of 0.90 (95% CI, 0.84-0.95), 86% sensitivity, and 89% specificity. Interpretation: These results show that eNose assessment may detect early stages of lung cancer in patients with COPD and therefore may be of value in screening this risk group. Patients with COPD are at higher risk of lung cancer developing, with studies showing a relative risk of twofold to fourfold compared with the general population.1de Torres J.P. Marín J.M. Casanova C. et al.Lung cancer in patients with chronic obstructive pulmonary disease—incidence and predicting factors.Am J Respir Crit Care Med. 2011; 184: 913-919Crossref PubMed Scopus (225) Google Scholar Although several biomarkers are candidates for lung cancer discovery, such as autoantibodies, complement fragments, microRNA, circulating DNA, DNA methylation, RNA and protein profiling, and metabolomics,2Seijo L.M. Peled N. Ajona D. et al.Biomarkers in lung cancer screening: achievements, promises, and challenges.J Thorac Oncol. 2019; 14: 343-357Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar no validated biomarkers have been discovered yet that can identify patients with COPD who are at a higher risk of lung cancer developing. During the past decade, screening studies using low-dose CT (LDCT) imaging have shown significant reductions (up to 39% in women) in lung cancer mortality rates among high-risk individuals, who were defined based on tobacco use history (status, pack-years, quit time) and age (50-75 years).3Aberle D.R. Adams A.M. Berg C.D. et al.Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med. 2011; 365: 395-409Crossref PubMed Scopus (7282) Google Scholar, 4Ru Zhao Y. Xie X. de Koning H.J. Mali W.P. Vliegenthart R. Oudkerk M. NELSON lung cancer screening study.Cancer Imaging. 2011; 11 (spec no A(1a)): S79-S84Crossref PubMed Scopus (145) Google Scholar, 5de Koning H.J. van der Aalst C.M. de Jong P.A. et al.Reduced lung-cancer mortality with volume CT screening in a randomized trial.N Engl J Med. 2020; 382: 503-513Crossref PubMed Scopus (1347) Google Scholar Interestingly, a recently published study showed that patients with COPD are at higher risk of lung cancer regardless of tobacco use history.6Park H.Y. Kang D. Shin S.H. et al.Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.Thorax. 2020; 75: PubMed Scopus Google Scholar the of screening be by the risk of to COPD and the inclusion of these patients in lung cancer screening L.M. risk for after lung of a pulmonary an analysis of Med. 2011; PubMed Scopus Google et risk of mortality and for lung cancer Thorac Full Text Full Text PDF PubMed Scopus Google Scholar by imaging and follow-up to patients with C. et in low-dose computed screening for lung Med. PubMed Scopus Google Scholar an for an and that can be at the of a that can the of high-risk for follow-up screening is to in clinical Molecular profiling of exhaled breath by electronic nose (eNose) technology may qualify for the early detection of lung L.M. Peled N. Ajona D. et al.Biomarkers in lung cancer screening: achievements, promises, and challenges.J Thorac Oncol. 2019; 14: 343-357Abstract Full Text Full Text PDF PubMed Scopus (238) Google Scholar eNose technology is an that advanced for analysis of the of in exhaled M. et and early diagnosis of lung Thorac Oncol. Full Text Full Text PDF PubMed Scopus Google The electronic nose technology in clinical a 2019; PubMed Google Scholar The of in exhaled breath the in the both in the and in and Google Scholar analysis of these for in lung M. et and early diagnosis of lung Thorac Oncol. Full Text Full Text PDF PubMed Scopus Google the nose is to the lung Full Text Full Text PDF PubMed Scopus Google D. cancer breath Respir Med. 2019; PubMed Scopus Google Scholar using differences in exhaled of patients with COPD, patients with lung and have been demonstrated by The electronic nose technology in clinical a 2019; PubMed Google R. et electronic nose in the of patients with lung cancer and Full Text Full Text PDF PubMed Scopus Google Scholar, M. of of lung cancer and chronic obstructive pulmonary disease using the electronic Breath 2020; PubMed Scopus Google Scholar, D. M. et in patients with lung and follow-up PubMed Scopus Google Scholar, M. of cancer exhaled a PubMed Scopus Google Scholar, et in breath for of lung PubMed Scopus Google Scholar that and that in early lung cancer can be from exhaled breath using an study to the diagnostic of exhaled breath analysis by eNose for the between patients with COPD and those with lung cancer in a training and validation and the prospective of early lung cancer in COPD. using this and the study the of the for of et for diagnostic and Scopus Google Scholar and the of a for or of a for or diagnosis the Med. PubMed Scopus Google Scholar BreathCloud is a real-world study in and patients with a or diagnosis of asthma, COPD, or lung R. et and by in chronic of the diagnostic Respir Scopus Google Scholar All patients who the lung for diagnostic and monitoring in day-to-day care were The reported data results from 682 patients with COPD and 211 patients with lung cancer who were between and Patients with COPD were according to the for et for the and of J Respir Crit Care Med. PubMed Scopus Google Scholar and an diagnosis of lung cancer was based on Oudkerk M. et and advanced lung cancer clinical for and Oncol. Full Text Full Text PDF PubMed Scopus Google M. D. lung cancer clinical for and Oncol. Full Text Full Text PDF PubMed Scopus Google Scholar for in this study were the of or patients were not or able to tobacco or on were to the of breath analysis by eNose in clinical The of in that on in was not to be the and of this study that exhaled breath analysis by eNose to standard diagnostic R. et and by in chronic of the diagnostic Respir Scopus Google R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google R. van der et of electronic nose technology with validation of a for exhaled breath Breath PubMed Scopus Google Scholar the that was by the the of the eNose to was to the of whom The study an prospective, follow-up baseline patients with COPD eNose The patients with COPD were according to standard care, and the incidence of clinically diagnosed lung cancer was prospectively based on clinical by the patients prospectively for 2 years. diagnosis of lung cancer was with CT imaging and was based on Oudkerk M. et and advanced lung cancer clinical for and Oncol. Full Text Full Text PDF PubMed Scopus Google M. D. lung cancer clinical for and Oncol. Full Text Full Text PDF PubMed Scopus Google Scholar assessment of patients with COPD was using the COPD D. van and of the clinical COPD and chronic Med. Full Text Full Text PDF PubMed Scopus Google Scholar the after was used from data collected to inclusion. clinical data were collected for clinical care and subsequently were by with the Data Exhaled breath were in duplicate using a and clinically validated the R. et and by in chronic of the diagnostic Respir Scopus Google R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google R. van der et of electronic nose technology with validation of a for exhaled breath Breath PubMed Scopus Google et breath analysis by use of eNose a diagnostic for lung Respir 2020; PubMed Scopus Google Scholar The of different metal-oxide semiconductor for of exhaled of the same ambient air for by an to lung a breath by a to The were in to an analysis for data analysis. of the and the of the is published R. et and by in chronic of the diagnostic Respir Scopus Google R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar The of the eNose was using the standard eNose as was published R. et and by in chronic of the diagnostic Respir Scopus Google R. van der et of electronic nose technology with validation of a for exhaled breath Breath PubMed Scopus Google Scholar signal ambient air correction, and were the to the 2, to differences and the between the and the breath R. et and by in chronic of the diagnostic Respir Scopus Google R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar The and to breath were used for analysis. principal component analysis was to the of a to the principal with an of were P.A. The as a of the of of the Google Scholar The the and the to breath were to PCs that of the within the 1, 2, and PCs were for and validation based on eNose data from within the training the of the data is to the risk of in electronic nose are from using these in clinical of breath Breath Scopus Google R. of different for the of electronic nose PubMed Scopus Google Scholar were in both a training and validation defined by analysis as for for in and Scopus Google Scholar The PCs were compared between using The PCs that (P < between were for analysis. The were validated by linear discriminant analysis was using the The of linear discriminant analysis is to the of the defined and a and The is for eNose in electronic nose are from using these in clinical of breath Breath Scopus Google Scholar and is used in clinical studies exhaled breath analysis with the R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google R. van der et of electronic nose technology with validation of a for exhaled breath Breath PubMed Scopus Google R. et using exhaled breath analysis by electronic nose in a Scopus Google Scholar on the a discriminant was that between The of this was defined as the of patients in the training cross-validation was used to the value The discriminant were used to a receiver operating characteristic the area under the receiver operating characteristic curve and the discriminant from the training was in the validation and compared based on AUC a in the assessment of early lung the training and validation sets were and the accuracy, sensitivity, and for the between COPD and lung cancer were the study was to the the of COPD in the lung cancer on the of lung cancer from COPD was by patients with a diagnosis from the analysis 1, 1, based on a used three and to the eNose and and discriminant analysis. These have been used in R. and of for 2019; PubMed Scopus Google Scholar, M. for analysis of data and PubMed Scopus Google Scholar, for and by J Scholar and an of the of the different 1, to the of the to the linear discriminant analysis results linear discriminant analysis, and receiver operating characteristic curve analysis were used to the diagnostic of eNose analysis for the between patients with COPD who did and did not receive a clinical diagnosis of lung cancer within 2 years after inclusion. sensitivity, a and a were was to the duplicate of this was in the COPD that did receive a clinical diagnosis of lung cancer within 2 years was the different lung cancer stages linear was to eNose data based on the clinical on the analysis and results is in patients patients with COPD and 211 patients with lung were in this of whom patients patients with COPD and patients with lung were for training of the results and patients patients with COPD and patients with lung for validation of the results the training of tobacco use and showed significant differences (P < between patients with COPD and those with lung cancer. significant differences were between these in baseline in the validation the baseline of patients in the training and validation were for significantly different COPD (P < and lung cancer (P < of Patients COPD and the and use history of tobacco between COPD and lung cancer (P < between COPD and lung cancer (P < between COPD and lung cancer (P < between training and validation (P < between training and validation (P < between training and validation (P < between training and validation (P < between training and validation (P < between training and validation (P < are as or for lung lung between COPD and lung cancer (P < between training and validation (P < in a Data are as or for lung lung cancer. the training (P 2 (P < and 3 (P < were significantly different between patients with COPD and those with lung cancer. discriminant analysis showed a value of The AUC after cross-validation 0.89 (95% CI, The to discriminate between COPD and lung with 1, 2, and 3 as for the from the training was in an validation of patients with COPD and those with lung cancer in the validation were with a value of and an AUC of 0.86 (95% CI, 0.81-0.89). The results of the in the validation were and are in 3 and and as a assessment of early lung both the training and validation 2 (P < and 3 (P < were significantly different between COPD and lung cancer. were with a of and the AUC 0.86 (95% CI, patients with lung cancer with COPD from the analysis 2, a of and AUC of (95% CI, were the 682 patients with COPD, patients (5.4%) demonstrated clinically manifest lung cancer within 2 years after inclusion (P 2 (P < and 3 (P < showed a significant at baseline between the patients with COPD who did and did not receive a diagnosis of lung cancer within 2 years, with a value of The AUC after cross-validation 0.90 (95% CI, 0.84-0.95). of these patients with COPD were by eNose as lung cancer at baseline The of patients with COPD who demonstrated clinically manifest lung cancer in 86% sensitivity, 89% a of and a of of Patients COPD and 2 use history of tobacco between COPD and early lung cancer (P < between COPD and early lung cancer (P < between COPD and early lung cancer (P < between COPD and early lung cancer (P < are as or for lung lung between COPD and early lung cancer (P < in a Data are as or for lung lung cancer. The COPD that did receive a clinical diagnosis of lung cancer was early and advanced lung cancer 3 (P < was significantly different between early and and advanced and lung cancer. were with a of and an AUC that (95% CI, study showed that exhaled breath analysis using eNose is able to between lung cancer and COPD. These results were in an validation of the patients with COPD who received a clinical diagnosis of lung cancer within 2 years after inclusion in the were as lung cancer by eNose at The eNose was able to discriminate patients with COPD who subsequently received a lung cancer diagnosis from those who did not with 87% this is the prospective study of early lung cancer among patients with COPD by using exhaled of lung cancer have been demonstrated by using eNose The electronic nose technology in clinical a 2019; PubMed Google R. et electronic nose in the of patients with lung cancer and Full Text Full Text PDF PubMed Scopus Google Scholar, M. of of lung cancer and chronic obstructive pulmonary disease using the electronic Breath 2020; PubMed Scopus Google Scholar, D. M. et in patients with lung and follow-up PubMed Scopus Google Scholar, M. of cancer exhaled a PubMed Scopus Google Scholar, et in breath for of lung PubMed Scopus Google X. C. et of in for lung cancer screening and early Full Text Full Text PDF PubMed Scopus Google M. et lung cancer by profiling using an electronic a validation Scholar the past years, several have to the of exhaled breath analysis for between lung cancer and COPD, The study showed of lung cancer and COPD, and were et R. et electronic nose in the of patients with lung cancer and Full Text Full Text PDF PubMed Scopus Google Scholar showed significant differences in breath profiles of patients with lung patients with COPD, and in a eNose to were able to between the with study using showed that of several and were significantly higher in lung cancer compared with D. M. et in patients with lung and follow-up PubMed Scopus Google Scholar of in the breath of patients with lung cancer have been reported in The of using to identify patients with lung Breath 2011; PubMed Scopus Google Scholar, X. M. Y. et detection of lung cancer with imaging Google Scholar, Y. M. breath biomarkers in lung PubMed Scopus Google Scholar of the of the study by et D. M. et in patients with lung and follow-up PubMed Scopus Google Scholar is that of the was able to between the the with and was the of the and in biomarkers are not such as eNose that the of with are in the of The electronic nose technology in clinical a 2019; PubMed Google Scholar the used a and clinically validated eNose to an to exhaled breath R. et and by in chronic of the diagnostic Respir Scopus Google R. M. van der et of to in patients with lung cancer by electronic nose analysis of exhaled Oncol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar be that can significantly in and of as as used for analysis, or et of in breath analysis by electronic Breath Scopus Google Scholar a study using eNose 11 of patients with COPD were identified as lung cancer and of those patients received a clinical diagnosis of lung cancer within M. of of lung cancer and chronic obstructive pulmonary disease using the electronic Breath 2020; PubMed Scopus Google Scholar by the a of for training of the eNose be of the for The using a signal processing, and analysis using in to The study was a of the BreathCloud be that patients with COPD were from care and received a diagnosis clinically according to the for the patients with to COPD are managed at care by general of the disease are managed at care The of or COPD is shown to be with a higher risk of lung H.Y. Kang D. Shin S.H. et al.Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.Thorax. 2020; 75: PubMed Scopus Google Scholar the high lung cancer incidence in the study compared with that of et tobacco and risk of cancer and chronic obstructive pulmonary disease in and never in the prospective PubMed Scopus Google risk of lung cancer in chronic obstructive pulmonary prospective, Med. PubMed Scopus Google Scholar use is to the of exhaled and therefore is to be a in exhaled breath et biomarkers for lung cancer detection and assessment of of and PubMed Scopus Google Scholar Although of tobacco use the of 2 or tobacco use did be that are with tobacco use and that this exhaled breath of on exhaled breath and tobacco smokers: a Med. Scopus Google Scholar Although the of tobacco use in patients with COPD were higher in patients with lung cancer in the training no significant differences were between the in the validation this and of tobacco use did not significantly to the of or tobacco use is to have with a van C. et of on exhaled breath profiles in and COPD Scopus Google Scholar analysis demonstrated no significant differences tobacco use or of tobacco use in patients with COPD who received a lung cancer diagnosis compared with those who did lung cancer and lung cancer significantly to the of or PCs these baseline in the training and validation were for patients with COPD and those with lung cancer and were between the training and validation for lung cancer The validation patients with may in the in results between the training and validation of the of study is prospective, real-world and the use of an validation and for between lung cancer and COPD that the results of the training of the study is use of a validated The validation of the eNose was the of signal processing, ambient air correction, and data analysis as as the and of on breath R. van der et of electronic nose technology with validation of a for exhaled breath Breath PubMed Scopus Google Scholar study The real-world CT imaging at is a was at of the patients with COPD showed of lung cancer at that be for patients with COPD with a diagnosis of lung a baseline CT have the that imaging high rates is showing that these have in between and D.R. Adams A.M. Berg C.D. et al.Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med. 2011; 365: 395-409Crossref PubMed Scopus (7282) Google C. cancer a and 2019; Scopus Google Scholar, et computed for pulmonary in the Scopus Google Scholar, cancer J Respir Crit Care Med. PubMed Scopus Google Scholar The data that and were at the of exhaled breath the of of lung cancer. the breath profiles in these patients to the of that from both COPD and lung cancer. breath profiles of patients with COPD who subsequently demonstrated clinically manifest lung cancer were with those in whom COPD and lung cancer the of to be from cancer or or D. et is of 2020; PubMed Scopus Google Scholar Interestingly, the with early of lung cancer in COPD did not to the to lung cancer the was by 2 and the by 3 that early of clinically manifest lung cancer in patients with COPD by eNose analysis is not by that are with a of the be the of this to the for lung cancer is the of among patients with COPD. The of lung cancer screening are to age and tobacco use and show high D.R. Adams A.M. Berg C.D. et al.Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med. 2011; 365: 395-409Crossref PubMed Scopus (7282) Google Scholar is that COPD is a risk for lung cancer. the screening reported higher relative risk for in patients with COPD compared with patients COPD CI, et lung cancer screening with low-dose computed and results of the screening PubMed Scopus Google Scholar COPD been shown to be an risk for lung cancer regardless of the tobacco use of the a study demonstrated that those with COPD who have never used tobacco have a higher risk of lung cancer compared with those COPD who have never used H.Y. Kang D. Shin S.H. et al.Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.Thorax. 2020; 75: PubMed Scopus Google Scholar a of lung cancer may not be of the of and tobacco with COPD from screening H.Y. Kang D. Shin S.H. et al.Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study.Thorax. 2020; 75: PubMed Scopus Google cancer risk to for screening PubMed Scopus Google Scholar the of be higher patients with COPD who not use the screening for lung cancer by patients with COPD to be detection not results in but can the risk of of data that eNose technology can lung in early a for exhaled breath analysis by eNose identified patients with COPD in whom lung cancer subsequently became clinically within 2 years after inclusion. These results show that eNose assessment may a for early of patients with COPD at risk of and may by those who from diagnostic and early The have reported to that no was received for this

Topics & Concepts